Bard (company)
C. R. Bard, Inc., headquartered in Murray Hill, New Jersey, USA, was a developer, manufacturer, and marketer of medical technologies in the vascular medicine, urology, oncology, and surgical specialty fields. C. R. Bard marketed its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. An S&P 500 company with approximately 14,000 employees in 2015, Bard is perhaps best known for having introduced the Foley catheter in 1934.[citation needed]
| Company type | Subsidiary |
|---|---|
| Founded | 1907 |
| Founder | Charles Russell Bard |
| Headquarters | New Providence, New Jersey, U.S. |
Area served | Worldwide |
Key people | Timothy M. Ring (Chairman) & (CEO) |
| Products | Vascular, Urology, Oncology, and Surgical Specialties |
| Revenue | US$2.72B (FY 2010)[1] |
| US$730M (FY 2010)[1] | |
| US$509M (FY 2010)[1] | |
| Total assets | US$3.17B (FY 2010)[2] |
| Total equity | US$1.63B (FY 2010)[2] |
Number of employees | 14,000 (2015)[3] |
| Parent | Becton, Dickinson and Company |
In April 2017, C. R. Bard announced that it would be acquired by Becton, Dickinson and Company (BD).[4][self-published source] The transaction was completed later that year,[5] and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
History edit
C. R. Bard, Inc. was founded in New York City by Charles R. Bard in 1907. Bard's first business involved importing Gomenol, which was used to treat urinary discomfort.[6] The company formally incorporated in 1923, and three years later, in 1926, Charles R. Bard sold the company to John F. Willits and Edson L. Outwin for $18,000. Under Willits and Outwins, the company expanded into the catheter business, introducing the Foley catheter in 1934 and the America Woven Catheter in 1940.[citation needed]
In 1948, C. R. Bard's annual sales topped $1 million for the first time, and the company moved its headquarters from New York City to Summit, New Jersey. In 1954, a Bard scientist, Dr. DeBakey, developed the first arterial prosthesis.[citation needed] Three years later the company began selling Foley catheters that came in sterile packaging for the first time ever. Bard continued to innovate in the world of catheters, rolling out the bipolar temporary pacing catheter in 1958 and the first latex balloon catheter in 1960. In 1961, Bard expanded beyond catheters, and began manufacturing products related to cardiology, radiology, and anesthesiology.
C. R. Bard went public in 1963 and was listed on the New York Stock Exchange in 1968. Over time, the company introduced a variety of new health care products, and its net sales first exceeded $1 billion in 1994. Around 2012, Bard acquired the company Lutonix.[7]
On April 23, 2017, it was announced that C. R. Bard would be bought by BD for $24 billion.[8] On December 29, 2017, the acquisition was completed.[5]
Legal issues edit
Illegal kickback settlement edit
In 2006, a complaint was filed against C. R. Bard, alleging that the company paid illegal kickbacks to both physicians and consumers. In 2013, Bard agreed to pay $48.26 million to resolve the allegations relating to submitting false claims to Medicare.[9]
Vaginal mesh devices edit
The transvaginal mesh is a device that is surgically implanted into the vagina to strengthen pelvic muscles or organs, or to treat incontinence.
By 2010, Bard and other makers of vaginal mesh were being sued by women who alleged that the devices were responsible for their medical pain and injuries. Their legal cases cited poor design and unsafe materials, and claimed that some patients required "multiple surgeries to remove" the device.[10] In 2012, the U.S. Food and Drug Administration (FDA) required that Bard and other manufacturers study the rates of organ damage linked to the mesh devices.[10]
Although Bard maintained that their vaginal mesh was "safe and effective", they began negotiations in 2013 to settle the nearly 30,000 legal claims.[11] By August 2015, Bard had agreed to pay more than $200 million, thereby resolving about one-fifth of the outstanding lawsuits at that time.[10]
Inferior vena cava (IVC) filters edit
An inferior vena cava filter (or "blood clot filter") is a device that is percutaneously implanted in the IVC. It is used to prevent deep-vein blood clots in the legs from moving into the heart or lungs (a condition that can be fatal).
Introduced in 2002, Bard's Recovery brand IVC filter was associated with 27 deaths and several hundred non-fatal problems. A "confidential study commissioned by Bard showed that the Recovery filter had higher rates of relative risk for death, filter fracture and movement than all of its competitors." Bard never recalled the Recovery filter, but instead developed G2 series filters to replace it.[12]
On December 31, 2015, NBC News released their investigation of the G2 series filters. According to the NBC report, the G2 filter was just a modified version of the Recovery filter with "similar and potentially fatal flaws". Bard was reported to be aware of this shortly after the G2 was put on the market, but rather than recalling the filters, kept them on the market for five years. According to Bard and FDA records, at least 12 deaths and hundreds of problems had been linked to the G2 series filters.[12]
In 2018, an Arizona court ordered Bard to pay $1.6 million to a plaintiff for injuries sustained from a G2 IVC filter implanted in 2007, plus an additional $2 million in punitive damages.[13] Bard challenged the verdict, but in October 2020, a court of appeals refused to overturn the ruling.[14]
References edit
- ^ a b c C.R. Bard (BCR) annual SEC income statement filing via Wikinvest.
- ^ a b C.R. Bard (BCR) annual SEC balance sheet filing via Wikinvest.
- ^ "CR Bard at Yahoo! Finance
- ^ . Bard. 2017. Archived from the original on June 6, 2017.
- ^ a b "BD Completes Bard Acquisition, Creating New Global Health Care Leader" (Press release). Becton, Dickinson and Company. December 29, 2017 – via PR Newswire.
- ^ Hallet, Anthony; Hallett, Diane (1997). "Charles R. Bard [C.R. Bard, Inc.]". Entrepreneur Magazine Encyclopedia of Entrepreneurs. John Wiley & Sons. pp. 27–28. ISBN 0-471-17536-6.
During a trip to Europe, he encountered a medicine called Gomenol, derived from eucalyptus tree, which relieved his urinary discomfort.
(registration required)(Full text via Internet Archive.) - ^ George, John (September 5, 2012), , Philadelphia Business Journal, bizjournals.com, archived from the original on August 26, 2014, retrieved September 5, 2012(registration required)
- ^ "Becton Dickinson buys CR Bard for $24 billion to form medical supply giant; Bard shares surge 20%". CNBC. Reuters. April 23, 2017. from the original on April 24, 2017.
- ^ Tycko, Jonathan (August 31, 2013). "Top Whistleblower Settlements of 2013—To Date". National Law Review. III (243). from the original on November 13, 2013. Retrieved November 6, 2013.
The live link is to the first of three pages. All content available in a single page via Archive Link. - ^ a b c Feely, Jef (August 4, 2015). "Bard Said to Pay $200 Million to Settle Vaginal-Mesh Cases". Bloomberg. from the original on August 8, 2015. Retrieved January 1, 2016.
Archived copy provides free access to full article content. - ^ "C.R. Bard negotiating to settle thousands of lawsuits involving vaginal-mesh implants". NJ.com. Bloomberg News. September 30, 2013. Retrieved April 15, 2014.
- ^ a b Sandler, Tim; Gosk, Stephanie (31 December 2015). "Why Did Firm Keep Selling Problem Blood-Clot Filters?". NBC News. Retrieved 1 January 2016.
- ^ Steinberg, Julie (October 1, 2020). "Ninth Circuit Stands by Ruling OKing $3.6 Million Bard Judgment". Bloomberg Law. Retrieved January 16, 2023.
- ^ Grzincic, Barbara (August 13, 2020). "9th Circuit upholds bellwether plaintiff's win in Bard IVC filter MDL". In Brief. Reuters. Retrieved 2023-01-16.
External links edit
- Historical business data for C. R. Bard:
- SEC filings